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Abstract: Autophagy is an intracellular pathway by which lysosomes degrade and recycle
long-lived proteins and cellular organelles. The effects of ethanol on autophagy are complex but
recent studies have shown that autophagy serves a protective function against ethanol-induced
liver injury. Autophagy was found to also be protective against CYP2E1-dependent toxicity
in vitro in HepG2 cells which express CYP2E1 and in vivo in an acute alcohol/CYPE1-dependent
liver injury model. The goal of the current report was to extend the previous in vitro and
acute in vivo experiments to a chronic ethanol model to evaluate whether autophagy is also
protective against CYP2E1-dependent liver injury in a chronic ethanol-fed mouse model.
Wild type (WT), CYP2E1 knockout (KO) or CYP2E1 humanized transgenic knockin (KI),
mice were fed an ethanol liquid diet or control dextrose diet for four weeks. In the last week,
some mice received either saline or 3-methyladenine (3-MA), an inhibitor of autophagy, or
rapamycin, which stimulates autophagy. Inhibition of autophagy by 3-MA potentiated the
ethanol-induced increases in serum transaminase and triglyceride levels in the WT and KI
mice but not KO mice, while rapamycin prevented the ethanol liver injury. Treatment with
3-MA enhanced the ethanol-induced fat accumulation in WT mice and caused necrosis in
the KI mice; little or no effect was found in the ethanol-fed KO mice or any of the dextrose-fed
mice. 3-MA treatment further lowered the ethanol-decrease in hepatic GSH levels and
further increased formation of TBARS in WT and KI mice, whereas rapamycin blunted these
effects of ethanol. Neither 3-MA nor rapamycin treatment affected CYP2E1 catalytic activity or
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content or the induction CYP2E1 by ethanol. The 3-MA treatment decreased levels of Beclin-1
and Atg 7 but increased levels of p62 in the ethanol-fed WT and KI mice whereas rapamycin
had the opposite effects, validating inhibition and stimulation of autophagy, respectively.
These results suggest that autophagy is protective against CYP2E1-dependent liver injury in
a chronic ethanol-fed mouse model. We speculate that autophagy-dependent processes such
as mitophagy and lipophagy help to minimize ethanol-induced CYP2E1-dependent oxidative
stress and therefore the subsequent liver injury and steatosis. Attempts to stimulate autophagy
may be helpful in lowering ethanol and CYP2E1-dependent liver toxicity.
Keywords: chronic ethanol; cytochrome P450 2E1 (CYP2E1); autophagy protection;
hepatotoxicity; oxidative stress; 3-methyladenine; rapamycin

1. Introduction
Autophagy is an intracellular pathway by which lysosomes degrade and recycle long-lived proteins
and cellular organelles. This pathway degrades cellular components that are damaged or are needed to
generate substrates that maintain cellular energy homeostasis under conditions of limited nutrients or
stress [1–5]. The regulation of this process is complex and controlled by the coordinated actions of
autophagy-related genes (Atgs). Removal of damaged mitochondria by mitophagy or of lipid droplets
by lipophagy are selective forms of macroautophagy [6–8]. Removal of damaged mitochondria protects
the cell against mitochondrial oxidative stress, while removal of lipid droplets limits the accumulation
of lipids by hepatocytes. Defects in lipophagy can contribute to hepatic steatosis. Interestingly, hepatocyte
lipid accumulation also decreases autophagy, indicating that steatosis might be a mechanism of defective
hepatic autophagy [6,9,10]. Autophagy is decreased in certain hepatic and pancreatic diseases e.g.,
1-antitrypsin deficiency and non-alcoholic fatty liver disease, but is increased in nutrient deficiency
and hepatitis B infection [8,10,11]. In general, autophagy is considered as a cell survival pathway but
one that can also mediate cell death under certain conditions or when overactivated.
Alcohol-induced liver injury (ALD) is a significant global health problem and a leading cause of
death worldwide. The mechanisms by which ethanol treatment causes cell death are still not clear. Many
of the hepatic toxic effects of ethanol have been linked to its metabolism in the liver. Ethanol-induced
liver pathology has been shown to correlate with CYP2E1 levels and lipid peroxidation [12–16]. The
biochemical and toxicological properties of CYP2E1 have been widely studied [17–20]. CYP2E1 is
induced under a variety of pathophysiological conditions such as fasting, diabetes, obesity and high fat
diet, by drugs, in non-alcohol-induced steatohepatitis and by alcohol [21–26]. Autophagy can either be
increased or decreased by ethanol depending on the model used, the dose, the tissue evaluated and the
experimental condition [27–35]. While the effects of ethanol on autophagy are complex and require
further study, it is becoming clear that autophagy serves a protective function against ethanol-induced
liver injury [4,28,29]. Chronic ethanol consumption was recently shown to increase autophagy [31,34]
and in some cases this increase was associated with a decrease in activity of the other major cellular
proteolytic system, the proteasome complex [35].
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To our knowledge, there have been no reports as to whether macroautophagy is protective against
CYP2E1 elevation of ROS, fatty liver and liver injury after chronic ethanol treatment or promotes these
responses by the liver to ethanol. The rationale for this is that CYP2E1 plays a role in ethanol-induced
oxidant stress, fatty liver and liver injury. Autophagy in some settings is protective against cell injury,
while in other settings, autophagy can promote cell toxicity. If autophagy is protective against chronic
ethanol/CYP2E1 toxicity, attempts to stimulate autophagy may prove to be helpful in lowering
ethanol-induced liver injury. If autophagy promotes ethanol/CYP2E1 toxicity, inhibitors of autophagy
may help to ameliorate ethanol hepatotoxicity.
We have recently shown that ethanol-induced toxicity, fat accumulation and generation of reactive
oxygen species in HepG2 E47 cells which express CYP2E1 was potentiated by 3-methyladenine, an
inhibitor of autophagy but decreased by rapamycin, which stimulates autophagy [36]. No effect was
found with C34 control HepG2 cells which do not express CYP2E1. Similarly, the toxicity of several
agents activated by CYP2E1 such as CCL4 or a polyunsaturated fatty acid such as arachidonic acid or
depletion of GSH by buthionine sulfoximine in the E47 cells was enhanced by 3-MA or by SiRNA
against Atg 7 [37]. In an acute binge alcohol model, there was modest liver injury, fat accumulation and
increased ROS production in wild type and CYP2E1 knockin mice but not in CYP2E1 knockout mice [38].
These effects were magnified when 3-MA was also administered with the acute ethanol but were blunted
when rapamycin was given with the ethanol [38]. These experiments are supportive of autophagy as
being protective against ethanol/CYP2E1-dependent liver toxicity. The goal of the current report was to
extend the previous in vitro and acute in vivo experiments to a chronic ethanol model to evaluate whether
autophagy is also protective against CYP2E1-dependent liver injury after chronic ethanol treatment.
2. Results and Discussion
2.1. Results
2.1.1. Effect of Chronic Ethanol Treatment on Liver Injury in WT, KO and KI Mice
Chronic ethanol feeding produced small increases in serum ALT and AST levels in all mice; highest
levels (about 150–200 units/L) were found with the WT and KI mice as compared to the KO mice
(30–40 units/L) (Figure 1A,B). Serum TG levels were significantly elevated by the chronic ethanol
feeding to WT and KI mice but not to the KO mice (Figure 1C).
Histological evaluation showed no changes in liver pathology in any of the dextrose-fed mice [39].
The ethanol feeding produced an increase in liver fat accumulation in the WT and KI mice, but not the
KO mice as compared to the dextrose-fed mice (Figure 2).
The steatosis scores were the following: WT-dextrose 0.95 ± 0.20; WT- ethanol 3.2 ± 0.6: KO-dextrose
0.5 ± 0.1; KO-ethanol 0.6 ± 0.1: KI-dextrose 0.2 ± 0.05; KI-ethanol 1.8 ± 0.4. The necroinflammation
scores were 2 ± 0.6 for the ethanol-fed KI mice and below 0.2 for all the others. These results support
the concept that CYP2E1 contributes to ethanol-induced liver injury and fat accumulation.
2.1.2. Effect of 3-MA and Rapamycin on Chronic Ethanol-Induced Liver Injury
Treatment with 3-MA caused a significant further increase in ALT and AST levels in the ethanol-fed WT
and KI mice but not the KO mice (Figure 1A,B). There was no effect by 3-MA in any of the dextrose-fed
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mice on serum transaminase levels. Treatment with rapamycin produced a decrease in ALT and AST
levels in the ethanol-fed WT and KI mice but had no effect in the KO mice fed ethanol or any of the
dextrose-fed mice (Figure 1A,B). The combined treatment with ethanol plus 3-MA elevated serum TG
three-fold over the increase produced by ethanol alone in the WT and KI mice, but not the KO mice. In
contrast, the combined treatment of ethanol plus rapamycin decreased serum TG levels in the WT and
KI mice as compared to ethanol alone feeding; no effect by rapamycin was found in the ethanol-fed KO
mice or in any of the dextrose-fed mice (Figure 1C).

Figure 1. 3-MA promotes but rapamycin prevents chronic ethanol induced liver injury in
WT and KI mice. WT, KO and KI mice were fed with a Lieber-DeCarli liquid diet for four
weeks. In the last week some mice were received an IP injection of saline, 3-MA or
rapamycin once a day for seven days. ALT (A) and AST transaminase activities (B) and
levels of triglyceride (TG) (C) were determined in the serum. &, p < 0.05 compared with
Dextrose control, n = 4; *, p < 0.05 compared with alcohol alone-treated mice, N = 4.
The 3-MA treatment further elevated the steatosis in the ethanol-fed WT but not KO mice, and
produced necrosis in the ethanol-fed KI mice (Figure 2). Treatment with rapamycin blunted the steatosis
in the ethanol-fed WT mice and the necrosis in the ethanol-fed KI mice without any effect in the KO
mice (Figure 2). No liver pathology was observed in any of the dextrose-fed mice either in the absence
or presence of 3-MA or rapamycin.
2.1.3. Effect of 3-MA and Rapamycin on Chronic Ethanol-Induced Oxidative Stress and CYP2E1
Chronic ethanol feeding produced a decrease in total GSH levels in the liver ranging from 65% in the
WT mice to 30% in the KO mice (Figure 3A).
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Figure 2. 3-MA enhances liver toxicity in WT mice and KI mice whereas rapamycin is
protective against liver injury. Chronic alcohol fed WT, KO and KI mice were treated with
saline, 3-MA or rapamycin as mentioned in the legend to Figure 1. Liver slides were prepared
for H&E staining and the extent of liver injury including steatosis and necrosis was observed
under a light microscope. Arrowheads point to lipid droplets, and the arrow points to
necroinflammation.
Treatment with 3-MA further lowered GSH levels in the ethanol-fed WT and KI mice but not the KO
mice, whereas treatment with rapamycin blunted the ethanol-induced lowering of hepatic GSH levels
(Figure 3A). Neither 3-MA nor rapamycin affected GSH levels in any of the dextrose-fed mice. Hepatic
lipid peroxidation, assayed via formation of TBARS, was elevated two-fold by the chronic ethanol
feeding to WT and to KI mice with no significant effect found with the KO mice (Figure 3B). The treatment
with 3-MA potentiated the ethanol elevation of TBARS in the WT and KI mice but not the KO mice,
whereas, in contrast, the treatment with rapamycin lowered the ethanol elevation of TBARS in these
mice (Figure 3B). No effects by 3-MA or rapamycin were observed in any of the dextrose-fed mice.
CYP2E1 catalytic activity was increased by the chronic ethanol feeding in the WT and KI mice; as
expected, little or no activity was seen in the KO mice (Figure 4). Neither treatment with 3-MA nor with
rapamycin has any effect on the basal CYP2E1 activity found in any of the dextrose-fed mice or in the
elevated activity found with the ethanol-fed WT and KI mice (Figure 4). Immunoblots to assay the levels
of CYP2E1 protein confirmed that neither 3-MA nor rapamycin had any effect on the levels of CYP2E1
in the dextrose-fed WT or KI mice or the ethanol-fed WT or KI mice [38].

Biomolecules 2015, 5

2664

Figure 3. 3-MA enhances while rapamycin blunts oxidative stress in chronic alcohol-fed
WT and KI mice. GSH levels (A) in WT, KO and KI mice. 3-MA potentiates the decline in
GSH produced by ethanol whereas rapamycin prevents this decrease of GSH in WT and KI
mice; TBARS (B) are elevated by ethanol feeding in WT and KI but not in KO mice. 3-MA
enhances ethanol induced TBARS but rapamycin lowers this increase. &, p < 0.05 compared
with dextrose control; *, p < 0.05 compared with chronic alcohol alone, N = 4.

Figure 4. 3-MA and rapamycin administration do not modify CYP2E1 catalytic activity.
Liver microsomes were prepared from dextrose and ethanol-fed WT KO and KI mice treated
with or without 3-MA or rapamycin treatment. CYP2E1 activity was determined using
4-nitrophenol (PNP) as the substrate. *, p < 0.05 compared with dextrose control, N = 3.
2.1.4. Effects of 3-MA and Rapamycin on Levels of Autophagic Proteins.
To validate that 3-MA or rapamycin were stimulating or inhibiting autophagy, respectively, in the
chronic ethanol-fed mice and whether there was any modulation of their actions by CYP2E1, levels of
key proteins involved in the autophagic process such as Beclin-1, Atg 7 or p62 were determined. As
shown in Figure 5, 3-MA treatment caused a small but significant decline in the Beclin-1/-actin ratio
in the ethanol-fed WT and KI mice.
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Figure 5. Effect of chronic ethanol or ethanol plus 3-MA or rapamycin on levels of Beclin-1.
Beclin-1 levels in WT, KO and KI mice fed with alcohol or dextrose with or without 3-MA
or rapamycin administration were determined by immunoblots. *, p < 0.05 compared with
alcohol-alone fed or dextrose-alone fed mice. Results are calculated from four mice in each
group, N = 4, although two to three blots are actually shown.
Rapamycin produced an increase in Beclin-1 in the ethanol-fed WT and KI mice, and a small increase
in the dextrose-fed WT and KI mice. No effects by 3-MA or rapamycin were found with the ethanol- or
dextrose-fed KO mice. Similar results were found with respect to levels of Atg 7 as 3-MA produced a
decrease in the Atg 7/-actin ratio in the ethanol-fed WT and KI mice whereas rapamycin elevated this
ratio more than two-fold in the WT and KI mice (Figure 6). 3-MA had no effect on Atg 7 levels in the
ethanol or dextrose fed KO mice (Figure 6). There was a smaller but still significant increase by
rapamycin in Atg 7 levels in the ethanol-fed KO mice (Figure 6) as well as very small increases in the
dextrose-fed mice.
With respect to levels of p62 which typically shows the opposite response as do Beclin-1 and Atg 7
autophagic proteins to modulators of autophagy, the 3-MA treatment increased the p62/-actin ratio in
the ethanol-fed WT and KI mice but not the KO mice (Figure 7). Rapamycin produced a decline in levels
of p62 in the ethanol-fed WT mice but had no effect in the KI mice or the KO mice (Figure 7).
Taken as a whole, the decrease in Beclin-1 and Atg 7 coupled to the increase in p62 supports the
inhibition of autophagy by 3-MA, while the opposite effects of rapamycin are supportive of a stimulatory
effect on autophagy by this compound.
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Figure 6. Effect of chronic ethanol or ethanol plus 3-MA or rapamycin on levels of Atg 7.
Atg 7 levels in WT, KO and KI mice fed with alcohol or dextrose with or without 3-MA or
rapamycin administration were determined by immunoblots. *, p < 0.05 compared with
alcohol-fed alone or dextrose fed alone mice. Results are calculated from four mice in each
group, N = 4, although two to three blots are shown.
3. Discussion
Ding and colleagues [28,40] were among the first to report that autophagy protects against liver injury
from acute alcohol in vivo and in vitro addition of ethanol to hepatocytes, and suggested that in response
to alcohol, the liver might upregulate autophagy to selectively remove damaged mitochondria and to
limit lipid accumulation. FOXO3a appears to play a critical role in this acute ethanol upregulation of
autophagy [41]. Eid et al. [34] showed that autophagy was elevated by chronic ethanol feeding to rats and
Yin and colleagues [31] reported that autophagic flux was increased by chronic ethanol feeding to mice
for four weeks. The chronic ethanol-induced fat accumulation and liver injury was enhanced when autophagy
was decreased by chloroquine but decreased when autophagy was increased by carbamazepine [31]. This
protective action of autophagy was extended to nonalcoholic fatty liver [31]. Autophagy also was protective
against acetaminophen toxicity [42], a drug which is metabolically activated by several cytochrome P450s,
especially CYP2E1. Autophagy was protective against ethanol/CYP2E1-dependent toxicity in HepG2 cells
in vitro and against an ethanol/CYP2E1 binge acute model in mice in vivo [36–38,43].
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Figure 7. Effect of chronic ethanol or ethanol plus 3-MA or rapamycin on levels of p62.
p62 levels in WT, KO and KI mice fed with alcohol or dextrose with or without 3-MA or
rapamycin administration were evaluated by immunoblots. *, p < 0.05 compared with ethanol
alone-fed mice.
This protective action of autophagy against ethanol/CYP2E1 toxicity was extended in the current
study to a chronic ethanol feeding model. Inhibition of autophagy by treatment with 3-MA increased the
chronic ethanol elevation of serum transaminase and TG levels in WT and KI mice over the increases
produced by ethanol alone. Stimulation of autophagy by treatment with rapamycin lowered the
ethanol-induced elevation of serum transaminases and levels of TG in WT and KI mice. Smaller (ALT,
AST) or little (TG) increase was produced by ethanol in the KO mice, and the treatments with 3-MA or
rapamycin had little or no effect on these parameters in the KO mice. Histopathology showed fat
accumulation in the ethanol-fed WT and necrosis in the ethanol-fed KI mice but not the KO mice. Fat
accumulation was increased when autophagy was inhibited by 3-MA but decreased when autophagy was
stimulated by rapamycin. The 3-MA treatment of ethanol-fed KI mice resulted in liver necrosis rather than
more fat accumulation attesting to the protective effects of autophagy against chronic ethanol/CYP2E1
liver injury. Neither inhibition nor stimulation of autophagy by 3-MA or rapamycin had any effects on
the basal CYP2E1 catalytic activity or protein levels in the dextrose-fed mice or on the increased
catalytic activity and protein levels in the ethanol-fed mice. In this respect, the proteasome complex, not
autophagy, has been shown to be the major protease system promoting degradation of CYP2E1 and ethanol
induction of CYP2E1 is largely due to ethanol stabilization of CYP2E1 against proteasome-mediated
turnover [44–46].
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Autophagy may be activated by ROS as a cytoprotective mechanism but overactivation of autophagy
by ROS could lead to cell injury [47–50]. However, not all ROS generators increase autophagy [51] and
under some conditions ROS can inhibit autophagy [47,52,53]. CYP2E1 contributes to mechanisms by which
alcohol produces oxidative stress [39,54,55]. Chronic ethanol feeding caused a decline in hepatic GSH
levels and an increase in liver TBARS. Inhibition of autophagy by treatment with 3-MA caused a further
decline in GSH levels in WT and KI mice while stimulation of autophagy with rapamycin prevented the
decline in GSH and the increase in TBARs in WT and KI mice. Neither 3-MA nor rapamycin had any
effect on levels of GSH or TBARs in the ethanol-fed KO mice. These results suggest that autophagy
protects against chronic ethanol/CYP2E1-induced oxidative stress. Toxicity by arachidonic acid in HepG2
E47 cells was increased when autophagy was inhibited by SiRNA Atg 7 in association with an elevation
in ROS [37]. The antioxidant N-acetyl cysteine decreased this toxicity and the elevated ROS and
toxicity when autophagy was inhibited suggesting that ROS plays a role in the potentiation of CYP2E1
toxicity when autophagy is inhibited. Although mechanisms by which autophagy lowers the chronic
ethanol/CYP2E1-induced oxidant stress were not evaluated in the current study, neither CYP2E1 catalytic
activity or levels or the increase by ethanol were affected by 3-MA or rapamycin. We speculate that
removal of damaged mitochondria by mitophagy may be one mechanism for the prevention of oxidative
stress by autophagy. Studies on mitochondrial structure, function and bioenergetics will be helpful to
assess this possibility. Removal of accumulated lipid droplets by lipophagy may contribute to the
decrease in oxidant stress and levels of TBARS by autophagy. Autophagy-mediated lowering of oxidative
stress is likely to play a key role in the protection against CYP2E1-dependent liver injury after chronic
ethanol treatment. A simple scheme (Scheme 1) summarizing these results is shown below: The induction
of CYP2E1 by ethanol elevated ROS which play a role in damage to mitochondria and to lipid accumulation.
Removal of lipids and oxidized mitochondria by lipophagy and mitophagy prevents or lowers liver cell
injury whereas blocking these processes potentiates cell injury.
Immunoblot analysis showed that 3-MA treatment lowered the levels of Beclin-1 and Atg 7 while
increasing the levels of p62 in the chronic ethanol-fed mice reflective of inhibition of autophagy.
Rapamycin increased the levels of Beclin-1 and Atg 7 in these mice suggesting stimulation of autophagy.
Smaller or no effects by 3-MA or rapamycin were found with the KO mice in which the ethanol feeding
itself had little effect.
We have previously reported that binge alcohol treatment of KI mice or acute alcohol treatment of
WT mice lowers the LC3-II/LC3-I ratio and the levels of Beclin-1 and Atg 7 but increases the levels of
p62 and mTOR as compared to saline controls [38]. Little or no effect on levels of these proteins was
found in binge ethanol KO mice [38]. We interpreted these results as an inhibition of autophagic proteins
by alcohol similar to conclusions of others who found that ethanol lowered LC3-II and Beclin-1 levels
in hepatocytes and HepG2 cells [56] or in immune cells [30] or in a rat hepatoma cell line [32]. Such an
interpretation is not consistent with reports that acute and chronic ethanol treatment increases autophagy
and autophagic flux [28,31,34]. However, autophagic flux was not assayed in the studies reporting
ethanol lowering autophagic protein levels, including our studies. Lowering levels of autophagic proteins
could reflect a decline in autophagy but also could be due to increased autophagic degradation via elevated
autophagic flux. Further studies will be necessary to assay for actual autophagic flux in ethanol-fed or
acute ethanol-treated WT, KI and KO mice to evaluate whether CYP2E1 plays a role in the effects of
ethanol on autophagy. Based upon the studies showing that acute [38] and chronic (this study) ethanol
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alters levels of Beclin-1 or Atg 7 or p62 in WT and KI mice to a greater extent than in KO mice, CYP2E1
or CYP2E1-derived ROS appears to play a modulatory role in the effects of ethanol on autophagy.

Scheme 1. Model for chronic ethanol/CYP2E1-induced hepatotoxicity.
4. Experimental Section
4.1. Animal Model and Treatment
Wild type (WT) SV/129 mice were purchased from Charles River Laboratory. SV/129 background
CYP2E1 knockout (KO) and humanized CYP2E1 transgenic mice (knockin, KI) mice [57,58] were a
generous gift from Dr. Frank J. Gonzalez (Laboratory of Metabolism, National Cancer Institute, Bethesda,
MD, USA) and colonies were established at Icahn School of Medicine at Mount Sinai. All mice were housed
in temperature-controlled animal facilities with 12-h light/12-h dark cycles and were permitted consumption
of tap water and Purina standard chow ad libitum until being fed the liquid diets. The mice received
humane care, and experiments were carried out according to the criteria outlined in the Guide for the Care
and Use of Laboratory Animals and with approval of the Mount Sinai Animal Care and use Committee.
Twenty-four male mice, body weight, 25–30 g, of each genotype were initially fed the control
Lieber-DeCarli liquid dextrose diet (Bio-Serve, Flemingtown, NJ, USA) for 3 days to acclimate them to
the liquid diet. Afterward, half of the mice of each genotype (N = 12) were fed the Lieber-DeCarli liquid
ethanol diet (Bio-Serve) and the other half were fed the control liquid dextrose diet for a total of four
weeks. The content of ethanol was gradually increased every 3 days from 10% (1.77% vol/vol) of total
calories to 20% (3.54% vol/vol), 25% (4.42% vol/vol) and finally 30% (5.31% vol/vol). The control
mice were pair-fed the dextrose diet on an isoenergetic basis. The ethanol-fed mice had access to their
diets ad libitum, and the conditions of WT, KO, and KI mice were comparable. The amount of food
consumed by WT, KO and KI mice was approximately the same. In the fourth week, each ethanol and
dextrose diet fed group was divided into three subgroups. One group (N = 8) received saline ip, the
second group (N = 8) was injected ip with the autophagy inhibitor 3-methyladenine (3-MA) at a dose of
100 mg/kg/day for the last 7 days of ethanol or dextrose feeding, the third group (N = 8) was injected ip
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with the autophagy activator rapamycin (Rap) at a dose of 5 mg/kg, once a day for the last 7 days of ethanol
or dextrose feeding. At the end of treatment, the mice were terminated, blood collected and serum
prepared and liver was removed and cut into aliquots. Some aliquots were used for pathology and H&E
staining while other aliquots were stored at 80 °C for preparation of homogenates and further study.
4.2. Liver Injury Evaluation
Liver injury after chronic alcohol feeding with or without 3-MA or rapamycin administration was
evaluated by determining serum ALT, AST and TG levels; liver H&E staining; and two parameters
typically reflective of oxidative stress. ALT and AST levels in the serum was determined with a kit from
Pointe Scientific Inc. (Canton, MI, USA) using 15 μL of serum and kinetic determination of absorbance
at 340 nm.TG levels were determined with a kit from Pointe Scientific Inc. using 5 μL of serum and
assay of absorbance at 540 nm followed by comparison to a standard curve. Liver samples in 10%
buffered formaldehyde were processed in a blind fashion by the Mount Sinai Medical Center Pathology Core
for H&E staining and pathologic evaluation. Oxidative stress was evaluated by measuring lipid
peroxidation as formation of thiobarbituric acid reactive substances (TBARS) and levels of GSH in liver
homogenates as described previously [38,41,42].
4.3. CYP2E1 Activity and Protein Levels
To evaluate the possible effect of 3-MA and rapamycin directly on CYP2E1, CYP2E1 catalytic
activity and protein levels were determined in microsomes isolated from the alcohol and dextrose fed
mice of the 3 genotypes. CYP2E1 activity was determined by using p-nitrophenol (PNP) as substrate
and CYP2E1 protein was determined by immunoblots using a monospecific polyclonal CYP2E1 antibody
(a generous gift from Dr. Jerry Lasker) as described previously [38,43,54].
4.4. Levels of Autophagic Proteins
The effect of chronic ethanol or chronic ethanol plus 3-MA or chronic ethanol plus rapamycin
administration on levels of Beclin-1, Atg 7 and p62 were evaluated by immunoblots. Antibodies were from
Santa Cruz. The immunoblots were scanned and analyzed as the p62/-actin, Beclin-1/-actin and Atg
7/-actin ratios using a LI-COR Odyssey densitometer and software Image J from National Institutes of
Health (NIH).
4.5. Statistical Analysis
Statistical analysis was performed using one-way analysis of variance with subsequent post hoc
comparison by Scheffe. Values reflect means ± standard error. The number of experiments is indicated
in the figure legends.
5. Conclusions
In conclusion, autophagy is protective against ethanol/CYP2E1-dependent toxicity in vitro and
against acute ethanol/CYP2E1- and chronic ethanol/CYP2E1-dependent toxicity in vivo. Since CYP2E1
plays an important role in the toxicity of ethanol, drugs and carcinogens and is activated under various
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pathophysiological conditions such as diabetes, NASH and obesity, attempts to stimulate autophagy may
be beneficial in preventing/lowering CYP2E1/ethanol liver injury.
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